Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes

• Status: Unknown status
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Objectives: To investigate the treatment effect between Gastric Bypass and Exenatide in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism of Gastric Bypass and Exenatide.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wu Qinan
• Treatments: Exenatide

Criteria

Inclusion Criteria:

1. BMI ≥ 35kg/m2, With Type 2 Diabetes;

2. BMI32-34.9kg/m2, With Type 2 Diabetes, Insulin Therapy in Combination With Oral Administration of Drugs for 6 Months and HbA1c ≥ 7%;

3. Between the Ages of 18-60 Years;

4. Course of Type 2 Diabetes ≤ 5 Years;

5. ICA, IAA, GAD Are Negative , C-peptide Level is Not Less Than 0.3mg / L;

Exclusion Criteria:

1. non-diabetic patients , type 1 diabetes (serum insulin antibodies (ICA) or glutamic acid decarboxylase antibodies (GADA)-positive autoimmune diabetes), special type of diabetes, gestational diabetes;

2. patients who had liver or renal failure

3. severe infections in patients and patients who had cerebrovascular disease

4. patients who had heart failure

5. fasting serum insulin or 2-hour postprandial serum insulin were lower than normal (<20mmol / L)

6. course of diabetes> 5 years or age> 60 years or age <18 years